falsefalse

EHA 2024: Updates in the Treatment of CLL    - Episode 18

Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

, , , ,

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024
    EP. 2: Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL
    EP. 3: Frontline BTKi Selection
    EP. 4: Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib
    EP. 5: Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy
    EP. 6: Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL
    EP. 7: EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches
    EP. 8: Navigating Treatment Approaches for R/R CLL
    EP. 9: How Experts View MAIC Data That was Presented at EHA 2024
    EP. 10: BTKi Intolerance in Real-world Practice & Management Strategy
    EP. 11: Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities
    EP. 12: Approach to Hypertension Management With BTKi Treatment
    EP. 13: Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib
    EP. 14: Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing
    EP. 15: Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice
    EP. 16: TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices
    EP. 17: EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL
    Now Viewing
    EP. 18: Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673
    EP. 19: Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL
    EP. 20: Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies
    EP. 21: Clinical Pearls and Impacts to Practice from EHA 2024

    Video content above is prompted by the following:

    • BGB-16673

    Related Content:

    EHA 2024: Updates in the Treatment of CLL   UCI Health Chao Family Comprehensive Cancer CenterDana-Farber Cancer InstituteMayo ClinicColumbia University Herbert Irving Comprehensive Cancer CenterCity of HopeChronic Lymphocytic LeukemiaOncLive Peer Exchange®
    Dr Ghia on the Role of Fixed-Duration Ibrutinib Plus Venetoclax in CLL and Beyond
    "Halfway Technology": Is It Time to Seriously Discuss Transitioning From the Current Focus of Cancer Research?
    Vish Viswanath, PhD, of Dana-Farber Cancer Institute, Elected as Fellow of the American Association for the Advancement of Science
    x